{"entity":{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","aka":[],"tldr":"Scanning microscope slides and letting software measure things a pathologist cannot see, including predictions of who will benefit from a treatment.","summary":"Whole-slide imaging, scanning glass slides into gigapixel digital images, is now routine in large pathology laboratories. FDA-cleared tools: Paige Prostate (detection), ArteraAI Prostate (2025, first prognostic and predictive AI) and ArteraAI Breast (May 2026, risk stratification in early HR+/HER2- breast cancer). Foundation models (Virchow, UNI, CONCH, Prov-GigaPath) predict molecular status (MSI, HRD, HER2) from H&E alone.","status":"established","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Digital_pathology","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Digital_pathology"}],"tags":[],"related":["ai-pathology-to-adt","ai-oncology-clinic"],"cancers":[],"sections":["diagnostics","ai-computation"],"technologies":[],"targets":[],"drugs":["artera-ai-prostate","artera-ai-breast"],"companies":["artera","paige","pathai","ataraxis-ai","digistain","histowiz","ibex-medical-analytics","imagene-ai","nucleai","perimeter-medical-imaging-ai","valar-labs","x-zell","strand-ai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["analytical-cellular-pathology"],"dependsOn":["whole-slide-scanners","ai-compute-platforms"],"notes":[],"principle":"Gigapixel whole-slide images; tile-level self-supervised encoders aggregated to slide-level predictions.","strengths":["Cheap biomarker from routine slides","Consistent scoring (Ki-67, TILs, HER2)"],"limitations":["Scanner and stain domain shift","Explainability","Regulatory pathways for updates"]},"route":"/technologies/digital-pathology-ai/","neighbours":{"pairing":[{"id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/"},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"drug":[{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/"},{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/"},{"id":"paige-prostate","kind":"drug","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/"}],"company":[{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/"},{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/"},{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/"},{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/"},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/"},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/"},{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/"},{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/"},{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/"},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/"},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/"},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/"},{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/"},{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/"},{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/"},{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/"},{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/"}],"journal":[{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/"}],"technology":[{"id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/"},{"id":"ai-pathology-scoring","kind":"technology","name":"AI scoring of biomarkers and grade on pathology slides","route":"/technologies/ai-pathology-scoring/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"multiplex-immunofluorescence","kind":"technology","name":"Multiplex immunofluorescence","route":"/technologies/multiplex-immunofluorescence/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/"},{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/"},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/"},{"id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"term":[{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"cribriform-prostate-cancer","kind":"term","name":"Cribriform growth pattern in prostate cancer","route":"/terms/cribriform-prostate-cancer/"},{"id":"digital-pathology-wsi","kind":"term","name":"Digital pathology and whole-slide images (WSI)","route":"/terms/digital-pathology-wsi/"},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/"},{"id":"h-and-e-staining","kind":"term","name":"H&E staining (haematoxylin and eosin)","route":"/terms/h-and-e-staining/"},{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/"},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"paper":[{"id":"paper-asco-cap-er-pr-testing-guideline-jco-2010","kind":"paper","name":"American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","route":"/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/"},{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/"},{"id":"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","kind":"paper","name":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","route":"/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/"},{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/"}],"idea":[{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/"},{"id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/"},{"id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/"},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/"},{"id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/"},{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/"},{"id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/"},{"id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/"},{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/"},{"id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/"},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/"},{"id":"idea-tr2-her2-low-reference-materials","kind":"idea","name":"Calibrated reference slides so every lab scores HER2-low the same way","route":"/ideas/idea-tr2-her2-low-reference-materials/"},{"id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/"},{"id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/"},{"id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/"},{"id":"idea-data-federated-learning-imaging","kind":"idea","name":"Federated training of pathology and radiology models across hospitals","route":"/ideas/idea-data-federated-learning-imaging/"},{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/"},{"id":"idea-tnbc-pd-l1-assay-harmonisation","kind":"idea","name":"Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance","route":"/ideas/idea-tnbc-pd-l1-assay-harmonisation/"},{"id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/"},{"id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/"},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/"},{"id":"idea-data-open-deidentification-pipeline","kind":"idea","name":"One certified open-source de-identification pipeline for scans and slides","route":"/ideas/idea-data-open-deidentification-pipeline/"},{"id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/"},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/"},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/"},{"id":"idea-tr2-open-cdx-validation-sets","kind":"idea","name":"Public gold-standard datasets for validating every cancer biomarker test","route":"/ideas/idea-tr2-open-cdx-validation-sets/"},{"id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/"},{"id":"idea-tnbc-her2-ultralow-testing-uptake","kind":"idea","name":"Reflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan","route":"/ideas/idea-tnbc-her2-ultralow-testing-uptake/"},{"id":"idea-data-sequestered-prospective-benchmarks","kind":"idea","name":"Sequestered, prospectively collected benchmark datasets that no one can train on","route":"/ideas/idea-data-sequestered-prospective-benchmarks/"},{"id":"idea-acc-telepathology-district-network","kind":"idea","name":"Slide scanners in district hospitals wired to pathologists anywhere","route":"/ideas/idea-acc-telepathology-district-network/"},{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/"},{"id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/"},{"id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/"},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/"},{"id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/"},{"id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/"}],"institution":[{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/"},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/"},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/"}],"person":[{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/"},{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/"},{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/"},{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","route":"/people/thomas-fuchs/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"}]}}